Sage Therapeutics - SAGE Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last twelve months. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View SAGE analyst ratings or view top-rated stocks.

12 equities research analysts have issued 1 year price targets for Sage Therapeutics' stock. Their SAGE share price forecasts range from $37.00 to $73.00. On average, they anticipate the company's share price to reach $48.29 in the next year. This suggests a possible upside of 3.7% from the stock's current price.
View analysts price targets for SAGE or view top-rated stocks among Wall Street analysts.

Sage Therapeutics' stock was trading at $38.14 on January 1st, 2023. Since then, SAGE shares have increased by 22.1% and is now trading at $46.57.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our SAGE earnings forecast.

Sage Therapeutics will be holding an earnings conference call on Thursday, February 16th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Sage Therapeutics, Inc. (NASDAQ:SAGE) issued its quarterly earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($2.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.84) by $0.37. The biopharmaceutical company earned $1.44 million during the quarter, compared to analyst estimates of $2 million. Sage Therapeutics had a negative net margin of 7,895.27% and a negative trailing twelve-month return on equity of 32.76%. During the same quarter in the prior year, the firm posted ($2.03) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Sage Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.74%), Pinnacle Associates Ltd. (0.30%), Pinnacle Associates Ltd. (0.29%), Baillie Gifford & Co. (0.16%), Allspring Global Investments Holdings LLC (0.15%) and Hennion & Walsh Asset Management Inc. (0.12%). Insiders that own company stock include Barry E Greene, Barry E Greene, George Golumbeski and James M Frates.
View institutional ownership trends.

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SAGE stock can currently be purchased for approximately $46.57.

Sage Therapeutics (NASDAQ:SAGE) has a market capitalization of $2.77 billion and generates $6.31 million in revenue each year. The biopharmaceutical company earns $-457,890,000.00 in net income (profit) each year or ($8.63) on an earnings per share basis.

The company employs 471 workers across the globe.

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The official website for the company is www.sagerx.com. The biopharmaceutical company can be reached via phone at (617) 299-8380, via email at ir@sagerx.com, or via fax at 617-299-8379.